scorecardresearch
Sunday, Oct 02, 2022

Expert panel recommends EUA to Corbevax jab for 12-18 years

The committee’s recommendations will be taken up by the drug regulator for formal approval of the vaccine in the next few days.

India, India latest news, Biological E, Corbevax, Corbevax vaccine, covid, covid cases, coronavirus latest news, omicron cases, third wave, covid vaccine, indian expressAt present, India is administering Covid-19 vaccines to 15-18 years. (File)

The subject expert panel on Covid-19 vaccines on Monday recommended the drug regulator to grant emergency use authorisation to Hyderabad-based Biological E’s Corbevax for the age group of 12-18 years, subject to conditions, sources said.

The committee’s recommendations will be taken up by the drug regulator for formal approval of the vaccine in the next few days.

Corbevax is India’s first indigenously developed protein sub-unit vaccine against Covid-19. At present, India is administering Covid-19 vaccines to 15-18 years.

The expert panel on vaccine administration is expected to meet soon to take a decision to expand Covid-19 vaccination coverage from 12 years onwards.

Subscriber Only Stories
From the Opinion Editor: An election for the Congress partyPremium
From Nehru to JP, the political leaders mentored by GandhiPremium
Uttarakhand resort murder: Amid questions within, BJP may revamp Dhami go...Premium
From suicide to graft: After power shift in Mumbai, key cases go on the b...Premium

Corbevax is built on the traditional subunit vaccine platform: instead of using the whole virus, the platform triggers an immune response by using fragments of it, like the spike protein.

The sub-unit vaccine contains harmless S-protein; once the immune system recognises S protein, it produces antibodies as white blood cells that fight the infection. At present, only Bharat Biotech’s Covaxin can be administered to the adolescent population.

Bio E’s Corbevax includes an antigen developed by Texas Children’s Hospital Centre for Vaccine Development and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team. The Centre has already made an advance payment of Rs 1,500 crore to reserve 30 crore doses of Corbevax.

First published on: 15-02-2022 at 02:46:18 am
Next Story

Kasganj ‘custody death’: ‘Losing young son not easy, fight for justice even more difficult’

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement